• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
Tebubio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
News

PV-10's Assessment For Drug-Drug Interaction Potential

27/03/2014 by Jean-François Têtu, PhD No Comments

http://www.ncbi.nlm.nih.gov/pubmed/?term=24405273

The published research indicated that the risk of PV-10 causing clinically relevant drug-drug interactions is likely minimal. PV-10, a 10% solution of rose bengal that is currently under clinical investigation as a novel cancer therapeutic, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, minimizing the potential for systemic side effects.

The study was undertaken prior to initiation of the now ongoing testing of PV-10 plus sorafenib (cohort 2) in a clinical trial of PV-10 intralesional injection in hepatocellular carcinoma patients taking a stable dose of sorafenib (ClinicalTrials.gov Identifier: NCT00986661). Sorafenib is a competitive inhibitor of cytochrome P450 (CYP) drug metabolism enzymes and is reliant on the UDP-glucuronosyltransferase (UGT) pathway for efficient clearance.  CYP and UGT enzymes help to biotransform small lipophilic drugs like sorafenib into water-soluble excretable metabolites.

Provectus researchers collaborated with XenoTech’s experts to design the appropriate in vitro experiments necessary to assess the risk for potential liability when rose bengal is co-administered with other drugs in humans. Rose bengal, known for inducing singlet oxygen on exposure to light, can cause erroneous results in conventional in vitro test systems. These assay artifacts were shown to be test system dependent in DMPK studies. XenoTech scientists successfully tailored experiments to ascertain CYP and UGT inhibition potential in more appropriate model systems.

The lead author, Faraz Kazmi, a Senior Scientist at XenoTech said, “The FDA guidance for industry on drug-drug interactions requires an in vitro assessment of the potential liability for a new drug to engender drug-drug interactions. These experiments are important because they provide the basis for safe, rational clinical trial design and are important determinants toward the ultimate goal, which is patient safety.”

Dr. Craig Dees, PhD, CEO of Provectus said, “We were thrilled to collaborate with XenoTech on these important studies that not only support the PV-10 plus sorafenib study, but also have implications for treating melanoma patients.  Provectus has been fortunate to work with many CROs with innovative scientists, but XenoTech stands out for their focus on the unique scientific problem as demonstrated in their rapid, expert assay development, suitable for publication in a peer reviewed journal.”  Dr. Dees continued, “As we discuss our clinical results with regulatory authorities, we continue to be intensely committed to building all sections of the prescribing information for a future package insert for PV-10.”

The paper, titled “In vitro inhibition of human liver cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes by rose bengal: system-dependent effects on inhibitory potential,” was authored by Faraz Kazmi, Lois J. Haupt, Jennifer R. Horkman, Brian D. Smith and David B. Buckley from XenoTech, Eric A. Wachter, and Jamie M. Singer of Provectus.

 

Cell Sourcing - Cell Culture Technologies, Supplying Discovery Tools

Supporting iPS reprogramming

24/03/2014 by Jean-François Têtu, PhD No Comments

mRNA Reprogramming

In 2010, a method for integration-free reprogramming by transfecting modified mRNA reprogramming factors was published (1, 2). The use of mRNA to induce reprogramming of somatic cells overcomes the inherent problems incurred by introducing viral vectors and/or integrating DNA to target cells. mRNA reprogramming factors are titratable and controllable with regards to the ratios, concentrations, and timing of factor expression. The mRNA reprogramming system also poses none of the biosafety risks surrounding viral and DNA-based systems.

Continue reading
Cell Sourcing - Cell Culture Technologies, Supplying Discovery Tools

295 solutions for isolating primary cells

20/03/2014 by Jean-François Têtu, PhD No Comments
Primary cells, active enzymes and small molecules for stem cell and Drug discovery research

Human Pancreatic Islets - Prodo LaboratoriesIt is widely accepted that data obtained from primary cells is not only desired, but, most relevant when trying to study physiological interactions. Experimentation in primary cells allows a deeper and more physiologically relevant view into the cellular function of proteins and enzymes that will allow the design of more specific drugs with meaningful and specific targets.

Continue reading
Page 22 of 22« First...10«19202122

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • From RUO to IVD - the acronym guide to reagents' intended use
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
My Tweets

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com

 

Loading Comments...